MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
University of Texas Health Science Center at San Antonio
San Antonio, Estados UnidosUniversity of Texas Health Science Center at San Antonio-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2022
-
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Journal for immunotherapy of cancer, Vol. 10, Núm. 2